Answers are grounded in this paper and cite their sources.
Understanding downstream beta-adrenergic signaling pathways such as PDE3, phospholamban, and CaMKII may provide novel therapeutic targets for heart failure.
Beta-adrenergic receptor activation plays an important role in the progression of human heart failure and the treatment of patients with beta-blockers has greatly improved the outcome of the disease. However, heart failure still is one of the leading causes of death in various countries and there is an imperative need for additional targets for the treatment of the disease. Recent studies by various groups have analyzed the downstream signaling pathways activated in response to beta-adrenergic stimulation that have the potential to become important targets for future treatments of heart failure. This review focuses on the significance of these pathways in the pathophysiology of heart failure in response to beta-adrenergic stimulation. More specifically the roles of PDE3, phosphorylation of phospholamban, and CaMKII activation are extensively discussed.
No takes yet. Share an insight, caveat, or question.
Carmen C. Sucharov (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: